Crisdesalazine
This article, Crisdesalazine, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
This article, Crisdesalazine, has recently been created via the Articles for creation process. Please check to see if the reviewer has accidentally left this template after accepting the draft and take appropriate action as necessary.
Reviewer tools: Inform author |
Clinical data | |
---|---|
Trade names | GedaCure |
Other names | AAD-2004; AAD2004 |
Drug class | Microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor; Free radical scavenger |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C16H14F3NO3 |
Molar mass | 325.287 g·mol−1 |
3D model (JSmol) | |
| |
|
Crisdesalazine (INN ; developmental code name AAD-2004) is a microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and free radical scavenger which is under development for the treatment of Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, Parkinson's disease, and spinal muscular atrophy.[1][2][3] It was also under development for the treatment of arthritis, diabetes, pain, and pancreatitis, but development for these indications was discontinued.[1] Crisdesalazine is also approved under the brand name GedaCure for treatment of dogs with canine cognitive dysfunction.[4]
The drug was derived from salicylic acids like mesalazine (5-aminosalicylate), aspirin (acetylsalicylate), and sulfasalazine.[2] By inhibiting mPGES-1 (also known as prostaglandin E synthase (PTGES)), it blocks prostaglandin E2 production.[2][5] Crisdesalazine is described as having a dual action, additionally acting as a direct free radical scavenger.[2] Crisdesalazine is described as having anti-inflammatory, antioxidant, and neuroprotective effects.[3] It seems to have potentially superior therapeutic effects compared to nonsteroidal anti-inflammatory drugs (NSAIDs; or cyclooxygenase inhibitors) like ibuprofen, for instance having better selectivity and safety.[2][5]
As of February 2023, crisdesalazine is in phase 1 clinical trials for Alzheimer's disease, amyotrophic lateral sclerosis (ALS), depressive disorders, and Parkinson's disease and is in the preclinical stage of development for spinal muscular atrophy.[1] It was first described in the scientific literature by 2012.[6][3]
See also
References
- ^ a b c "Crisdesalazine". AdisInsight. 21 February 2023. Retrieved 19 October 2024.
- ^ a b c d e Nango H, Tsuruta K, Miyagishi H, Aono Y, Saigusa T, Kosuge Y (June 2023). "Update on the pathological roles of prostaglandin E2 in neurodegeneration in amyotrophic lateral sclerosis". Transl Neurodegener. 12 (1): 32. doi:10.1186/s40035-023-00366-w. PMC 10278279. PMID 37337289.
- ^ a b c Dunkel P, Chai CL, Sperlágh B, Huleatt PB, Mátyus P (September 2012). "Clinical utility of neuroprotective agents in neurodegenerative diseases: current status of drug development for Alzheimer's, Parkinson's and Huntington's diseases, and amyotrophic lateral sclerosis". Expert Opin Investig Drugs. 21 (9): 1267–308. doi:10.1517/13543784.2012.703178. PMID 22741814.
- ^ "GNT Pharma's GedaCure® Approved for the Treatment of Dogs With Cognitive Dysfunction Syndrome". BioSpace. 10 February 2021. Retrieved 19 October 2024.
- ^ a b Pereira-Leite C, Nunes C, Jamal SK, Cuccovia IM, Reis S (July 2017). "Nonsteroidal Anti-Inflammatory Therapy: A Journey Toward Safety". Med Res Rev. 37 (4): 802–859. doi:10.1002/med.21424. PMID 28005273.
- ^ Lima IV, Bastos LF, Limborço-Filho M, Fiebich BL, de Oliveira AC (2012). "Role of prostaglandins in neuroinflammatory and neurodegenerative diseases". Mediators Inflamm. 2012: 946813. doi:10.1155/2012/946813. PMC 3385693. PMID 22778499.
- Pending AfC submissions
- Pending AfC submissions in article space
- AfC submissions by date/19 October 2024
- Anti-inflammatory agents
- Antioxidants
- Enzyme inhibitors
- Experimental antidepressants
- Experimental drugs
- Experimental drugs for Alzheimer's disease
- Neuroprotective agents
- Veterinary drugs
- Nervous system drug stubs